Department of Medical Oncology, Ankara University, 06590, Cebeci/Ankara, Turkey.
Ankara University Cancer Research Institute, 06590, Cebeci/Ankara, Turkey.
Future Oncol. 2021 Jan;17(3):349-357. doi: 10.2217/fon-2020-0671. Epub 2020 Dec 24.
Using circulating tumor DNA (ctDNA) instead of historical clinicopathological factors to select patients for adjuvant chemotherapy (ACT) may reduce inappropriate therapy. MEDLINE was searched on 31 March 2020. Studies, including data related to the prognostic value of ctDNA in the colon cancer patients after surgery and after ACT, were included. The generic inverse-variance method with a random-effects model was used for meta-analysis. Four studies were included for this meta-analysis. ctDNA-positive colon cancer patients after surgery and ACT had a significantly increased risk of recurrence compared with ctDNA-negative patients. ctDNA is an independent prognostic factor, and this meta-analysis is a significant step for using ctDNA instead of historical prognostic factors in the adjuvant setting.
使用循环肿瘤 DNA（ctDNA）替代历史临床病理因素选择辅助化疗（ACT）患者，可能会减少不适当的治疗。2020 年 3 月 31 日在 MEDLINE 上进行了检索。包括与术后和 ACT 后 ctDNA 在结肠癌患者中的预后价值相关数据的研究被纳入。使用随机效应模型的通用逆方差法进行荟萃分析。本荟萃分析纳入了四项研究。术后和 ACT 后 ctDNA 阳性的结肠癌患者复发风险显著高于 ctDNA 阴性患者。ctDNA 是一个独立的预后因素，本荟萃分析是在辅助治疗中使用 ctDNA 替代历史预后因素的重要一步。
